Abbott augments its diabetes management portfolio with Bigfoot Biomedical acquisition

USA —Abbott Laboratories, Inc. has concluded its acquisition of Bigfoot Biomedical—an innovative force in intelligent insulin management systems.

While financial specifics remain undisclosed, the implications of this union are profound. At the core of this transformative acquisition is Bigfoot’s brainchild—Bigfoot Unity.

This intelligent insulin management system brings innovation to the forefront, seamlessly blending connected insulin pen caps with data from an integrated continuous glucose monitor (iCGM) and expert guidance from healthcare providers.

What sets it apart is the real-time dosage recommendations displayed on the digital pen cap screen, offering users precise insulin administration guidance.

Bigfoot’s Unity system is a testament to technology’s potential in healthcare. A customer-centric smartphone app, tightly linked to a cloud-based internet portal for healthcare providers, forms the backbone of this system.

It fosters remote care and is uniquely tailored to integrate seamlessly with Abbott’s renowned FreeStyle Libre technology.

Compatibility extends to FreeStyle Libre 2 sensors and an array of popular disposable basal and bolus insulin pen brands available in the United States.

Abbott’s quest for excellence in diabetes care receives a substantial boost through the Bigfoot Biomedical acquisition.

It propels Abbott’s FreeStyle Libre portfolio, already a leader in continuous glucose monitoring technologies, to new heights.

The ultimate objective is to craft a constellation of interconnected solutions that usher in a new era of precision and personalization in diabetes management.

A synergy of CGM leaders

Both Abbott and Bigfoot share a common goal: delivering affordable, user-friendly solutions to diabetes patients.

The acquisition weaves together two giants in the realms of continuous glucose monitoring (CGM) and insulin dosing support.

Their synergy promises an array of interconnected solutions designed to elevate the precision and accuracy of diabetes control.

The timing of this acquisition couldn’t be better. According to a research report by grandviewresearch.com, the global CGM devices market reached a valuation of US$7.82 billion in 2022 and is projected to grow at a robust CAGR of 4.4% by 2030.

As the demand for advanced diabetes management solutions continues to surge, Abbott’s strategic move positions it at the forefront of innovation.

Abbott’s Diabetes Care business has been on a remarkable trajectory, largely driven by the resounding success of its flagship continuous glucose monitoring system, FreeStyle Libre.

In 2023, FreeStyle Libre achieved a significant milestone by becoming the first and only CGM system to secure national reimbursement in France.

Additionally, it garnered FDA clearance for seamless integration with automated insulin delivery systems.

Furthermore, Abbott has actively collaborated with leading insulin pump manufacturers to synchronize their systems with Libre 2 and Libre 3.

In June 2023, the company forged a groundbreaking partnership with the American Diabetes Association (ADA) to launch a therapeutic nutrition program.

This groundbreaking initiative seeks to explore how diabetes technology, including CGM systems, can empower individuals with diabetes to make informed decisions about their dietary choices and physical activity.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.